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Abstract: Several recent works suggest a possible role of vitamin D
deficiency in the etiology or restless legs syndrome (RLS). We analyzed
the possible relationship of 2 common single nucleotide polymorphisms
(SNPs) in the vitamin D3 receptor (VDR) gene with the risk for RLS.
We studied the genotype and allelic variant frequencies of VDR
rs2228570 and VDR rs731236 SNPs in 205 RLS patients and 445
healthy controls using a TaqMan essay., Margarita Arroyo
nd Jose´ A.G. Agu´ndez, MD, PhD
carrying the allelic variant rs731236G had an earlier age at onset, and
those carrying the rs731236GG genotype had higher severity of RLS,
although these data disappeared after multivariate analyses. None of
the SNPs studied was related with the positivity of family history of
RLS.
These results suggest a modest, but significant association between
VDR rs731236 SNP and the risk for RLS.
(Medicine 94(47):e2125)
Abbreviations : CSF = cerebrospinal fluid, DNA =
deoxyribonucleic acid, DOPAC = dihydroxyphenylacetic acid, ET
= essential tremor, GABA = gamma-hydroxybutyric acid, iRLS =
idiopathic restless legs syndrome, IRLSSGRS = International
Restless Legs Syndrome Study Group Rating Scale, MAO-A =
monoamine oxidase A, PD = Parkinson’s disease, RLS = restless
legs syndrome, RR = relative risk, SNP = single nucleotide
polymorphism, VDR = vitamin D3 receptor, WED = Willis-Ekbom
Disease.
INTRODUCTION
G enetic factors are likely to be very important in the etiologyof restless legs syndrome (RLS orWillis-Ekbom disease—
WED), but all the responsible gene(s) remain(s) to be identified
(revised in reference).1 Genome Wide Association Studies
(showed association between the risk for RLS and variants
of several genes, including Protein Tyrosine Phosphatase
Receptor Type Delta (PTPRD, chromosome 9p24.1–p23)
BTB/POZ Domain Containing Protein 9 (BTBD9, chromosome
6p21), MEIS1 (chromosome 2p14p13), mitogen-activated
protein kinase 5/SKI family transcriptional corepressor
1 (MAP2K5/SKOR1, chromosome 15q23), and the variants
rs6747972 at chromosome 2p14, and rs3104767 at chromosome
16q12.1.1 Whole exome sequencing studies found association
or RLS risk with some variants in the protocadherin alpha
3 (PCDHA3, chromosome 5q31) in a German family.1
The pathophysiology of idiopathic RLS (iRLS) is not well
understood as well. Whereas iron deficiency and dopaminergic
dysfunction are the main pathogenic hypothesis, recent works
suggest the possible implication of neurotransmitters and/or
neuromodulators such as aspartate, glutamate, opiates, oracid (GABA) (revised in reference).2
ears, several interesting reports pointed
vitamin D deficiency (which eventually
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TABLE 1. Demographic Data of the Series Studied
2 |d cause alterations in the development of the dopaminergic
m),3,4 in the etiology of iRLS:RLS Patients Controlssyste
(1) A
Group (n¼ 205) (n¼ 445)
Age, years, mean 53.8 (15.0) 63.6 (14.6)case-control study found decreased serum 25-hydro-
xyvitamin D in female with iRLS, which was inversely
correlated with disease severity.5
Increased prevalence of RLS described in patients with
(SD)(2)
mAge range, years 20–92 17–104
Age at onset years, 43.9 (16.7) NAusculoskeletal symptoms with relatively lower when
compared with those patients of the same cohort with
higher serum 25-dihydroxyvitamin levels.6mean (SD)(3) I
Female % 170 (82.9%) 369 (82.9%)ncreased levels of vitamin D-binding protein in the CSF of
RLS patients found in a preliminary case-control study
using proteomic analysis of the CSF.7
Improvement in the severity of RLS symptoms with(4)
administration of vitamin D supplements to patients with
vitamin D deficiency found in an open-label study
involving 12 patients.8
Vitamin D3 (1,25-dihydroxyvitamin D3) receptor gene
(VDR, NR1I1 or PPP1R163; chromosome 12q13.11; Gene
ID 7421; MIM 601769) encodes the nuclear hormone receptor
for vitamin D3. This receptor has a similar sequence to the
thyroid and steroid receptors, belongs to a family of trans-acting
transcriptional regulatory factors and acts as a receptor for the
lithocolic acid. It is involved in mineral metabolism and other
metabolic pathways involved in cancer and in the immune
response (link http://www.ncbi.nlm.nih.gov/gene/7421).
VDR gene shows 2 common single nucleotide polymorph-
isms (SNP) in Caucasians: the SNP rs2228570 (Fok1), which
causes the amino acid substitution (Met 1 Thr), and the synon-
ymous SNP rs731236 (Taq1), which does not cause amino acid
substitution (Ile 352 Ile), but it has been studied with regard to
several clinical conditions. These SNPs have been associated
with the risk for multiple sclerosis by several studies, although a
meta-analysis of these studies did not confirm such association.9
The rs731236 and other 2 SNPs in the VDR gene showed lack of
association with Parkinson’s disease in a meta-analysis study.10
Despite VDR polymorphisms have not been mentioned
among the possible susceptibility genes for RLS in GWAS, it
seems to be reasonable, due the possible role of vitamin D
deficiency in the pathogenesis of RLS, to study the association
between SNPs related with vitamin D and the risk for RLS. For
this purpose, we genotyped rs2228570 (Fok1) and rs731236
(Taq1) in the VDR gene in Caucasian Spanish RLS patients
and controls.
PATIENTS AND METHODS
Patients and Controls
Two-hundred and five unrelated patients diagnosed with
iRLS according with established RLS diagnostic criteria,11,12
and 445 gender-matched healthy controls were included in the
study (Table 1). Consultant neurologists with expertise in
Movement Disorders recruited the RLS patients. Besides the
diagnosis of iRLS, the absence of previous neurological or
systemic diseases, and the exclusion of possible causes of
secondary RLS such as peripheral neuropathy, renal failure,
anaemia, rheumatoid arthritis, and exposure to drugs able to
induce or to aggravate RLS, were required previously to the
inclusion of patients in the study. For this purpose, RLS patients
underwent laboratory studies (blood count, routine biochemis-erum levels of vitamin B12, folic acid, and thyroid hor-
es, iron metabolism studies, proteinogram, rheumatoid
r, antinuclear antibodies, and nerve conduction studies).
www.md-journal.comRestless legs syndrome severity was assessed by using the
International RLS Study Group Rating Scale (IRLSSGRS).13
The 445 controls were healthy Caucasian Spanish indi-
viduals (none of them having RLS, tremor or other movement
disorders, or systemic diseases) matched by gender (275 of them
were recruited from the Infanta Cristina University Hospital,
Badajoz, Spain; and the remaining 270 were recruited at the
Clı´nica Universitaria de Navarra; Pamplona, Spain).
Ethical Aspects
All the participants were included in the study after giving
their written informed consent when the procedure of the study
was full explained. The Ethics Committees of Clinical Inves-
tigation of the University Hospital ‘‘Prı´ncipe de Asturias’’
(University of Alcala´, Alcala´ de Henares, Madrid, Spain), the
Clı´nica Universitaria de Navarra (Pamplona, Spain), the Infanta
Cristina University Hospital (Badajoz, Spain), and the Province
of Ca´ceres (Ca´ceres, Spain), approved the study, that was
conducted according with the principles enumerated in the
Helsinki Declaration of 1975. Most of the patients recruited
had participated in other previous case-control studies of
genetic association with the risk for RLS.14–18
Genotyping of VDR Polymorphisms
We studied 2 SNPs in the VDR gene. The rs2228570 SNP
causes the amino acid substitution Met 1 Thr and that desig-
nated as rs731236 is a synonymous Ile 352 Ile SNP. The former
SNP was selected because it is the only nonsynonymous VDR
SNP that shows a frequency >0.01 in Caucasian individuals.
The later SNP was selected because it is the only synonymous
VDR SNP that has a high frequency (0.40 in Caucasians) and
because it has several clinical associations. These 2 variants do
not show linkage between themselves (D0 ¼ 0.06; r2¼ 0.003)
according the 1000 genomes integrated phase 1.
Genomic DNA was obtained from peripheral leukocytes
and purified according to standard procedures. VDR genotyping
was carried out by means of custom TaqMan Assay (Applied
Biosciences Hispania, Alcobendas, Madrid, Spain) designed to
detect the SNPs rs2228570 (C_12060045_20) and rs731236
(C_2404008_10). The full procedure was reported elsewhere.9
Statistical Analysis
We used the DeFinetti program (http://ihg.gsf.de/cgi-bin/
hw/hwa1.pl), to assess the Hardy–Weinberg equilibrium, the
PLINK software19 to perform the allele and genotype analysis,
NA¼ not available, RLS¼ restless legs syndrome, SD¼ standard
deviation.and the PHASE v2.1.1 program20 to perform the haplotype
reconstruction, using a default model for recombination rate
variation with 1000 iterations, 500 burn-in iterations, and a
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
thinning interval of 1. The combination of haplotypes in the best
run (the one that showed the maximum consistency of results
across all runs) was used to obtain diplotypes.21
Statistical analyses were performed using the SPSS 19.0
for Windows (SPSS Inc, Chicago, IL). The x2 or Fisher tests
were used to calculate the intergroup comparison values when
appropriate, and the 95% confidence intervals were calculated
as well. Multiple comparison of means was done by using the
Kruskal–Wallis test for independent samples, and correction for
multiple testing (Pc values) was done with the False Discovery
Rate procedure.22
The determination of the sample size was done from
variant allele frequencies observed in control individuals with
a genetic model analyzing the frequency for carriers of the
disease gene with an RR value¼ 1.5 (P¼ 0.05). The statistical
power for 2-tailed associations for the presence of the SNPs
identified in this study (rs2228570 and rs731236) was 81.9%,
and 82.6%. The Breslow–Day test was used to perform analysis
for heterogeneous genetic association (homogeneity test).
We calculated the negative predictive value (NPV) as d/r2
ratio (d¼ number of control individuals with the risk factor
absent; r2¼ sum of patients and controls with the risk factor
absent).23
RESULTS
The frequencies of the rs2228570 and rs731236 genotypes
and allelic variants were in Hardy–Weinberg’s equilibrium,
both in RLS patient and control groups (Table 2). The frequen-
cies of rs731236AA genotype and rs731236A allele were sig-
nificantly lower in RLS patients than in controls, both in the
whole series (Table 2) and in female gender (Table 3), and
remained significant after multiple comparison analysis accord-
ing the false discovery rate correction. Armitage’s test for trend
revealed a gene-dose effect for the whole series (chi
square¼ 7.09; P¼ 0.00773), and for women (chi square¼ 9.34;
P¼ 0.00224), which suggest an incomplete penetrance. The
Breslow–Day test indicates that the association was homo-
geneous (P¼ 0.284 and P¼ 378), for the whole series, and for
women, respectively. Restless legs syndrome patients carrying
the allelic variant rs731236G had an earlier onset of RLS
Medicine  Volume 94, Number 47, November 2015symptoms (Table 4), and RLS patients with rs731236GG
genotype showed higher severity of RLS symptoms
(Table 4). The frequencies of the rs2228570 genotypes and
TABLE 2. VDR Genotypes and Allelic Variants of Patients With RL
Number (Percentage; 95% Confidence Intervals)
Genotypes
RLS Patients
(N¼ 205, 410 Alleles)
C
(N¼ 44
VDR rs2228570 G/G 85 (41.5; 34.7–48.2) 197 (44
A/G 91 (44.4; 37.6–51.2) 198 (44
A/A 29 (14.1; 9.4–18.9) 50 (11
VDR rs731236 A/A 63 (30.7; 24.4–37.0) 188 (42
A/G 112 (54.6; 47.8–61.4) 207 (46
G/G 30 (14.6; 9.8–19.5) 50 (11
Alleles
VDR rs2228570 G 261 (63.7; 59.0–68.3) 592 (66
A 149 (36.3; 31.7–41.0) 298 (33
VDR rs731236 A 238 (58.0; 53.3–62.8) 583 (65
G 172 (42.0; 37.2–46.7) 307 (34
CI¼ confidence interval, NPV¼ negative predictive value, OR¼ odds ra
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.allelic variants did not differ significantly between RLS
patients and controls (Table 2), were not influence by gender
(Table 3), and were unrelated both with the age at onset of RLS
(Table 4) and with the severity of RLS symptoms (Table 4). The
distribution of genotypes and allelic frequencies of the 2 SNPs
studied was similar in RLS patients with positive family history
of RLS than in those with negative family history of RLS
(Table 5).
Linear regression under the standard additive model,
which included in a single model the genotypes, gender, age,
VDR Gene and Restless Legs Syndromeage at onset, ferropenia, and IRLSSGRS, was performed. Aside
from the association of the SNP rs731236 with RLS risk, none
of the putative associations were statistically significant.
DISCUSSION
Familial RLS shows usually an autosomal dominant
inheritance pattern (less frequently, nonmendelian or autosomal
recessive patterns have been described). To date, at least 8
genes/loci have been identified in linkage studies. Association
between several variants of the PTPRD, MEIS1, BTBD9, and
MAP2K5/SKOR1 genes with the risk of developing RLS have
been found in GWAS, and between the PCDHA3 gene and the
risk for RLS in an exome sequencing study (revised in1). The
results of the few case-control association studies reported in
RLS are inconclusive (revised in1). Previous case-control
association studies reported by our group involving the same
cohort of the present study showed a weak association between
heme-oxygenase 1 (HMOX1) rs2071746 polymorphism and the
risk to develop RLS,18 whereas no association was found with
several SNPs in the microtubule-associated protein tau
(MAPT),14 dopamine receptor D3 (DRD3),15 solute carrier
family 1-(glial high affinity glutamate transporter-), member
2 (SLC1A2),16 and nitric oxide synthase 1 (neuronal) (NOS1 or
nNOS) genes.17
Vitamin D has several important effects on the dopamin-
ergic system. Developmental vitamin D deficiency in rats
induces increase in dopamine content in the cortex and hypo-
thalamus, and increase in dihydroxyphenylacetic (DOPAC)
acid (one of the main metabolites of dopamine) and noradre-
nalin levels in the cortex,24 increase in dopamine transporter
density in the striatum and of affinity in the nucleus accum-
bens.25
S and Healthy Volunteers. The Values in Each Cell Represent:
ontrols
5, 890 Alleles) OR (95% CI), P; NPV (95% CI)
.3; 39.7–48.9) 0.89 (0.63–1.26); 0.503; 0.67 (0.64–0.71)
.5; 39.9–49.1) 1.00 (0.70–1.41); 0.980; 0.68 (0.65–0.72)
.2; 8.3–14.2) 1.30 (0.77–2.18); 0.292; 0.69 (0.68–0.71)
.2; 37.7–46.8) 0.61 (0.42–0.88); 0.005; 0.64 (0.62–0.67)
.5; 41.9–51.2) 1.39 (0.98–1.92);0.055; 0.72 (0.68–0.76)
.2; 8.3–14.2) 1.35 (0.81–2.26); 0.221; 0.69 (0.68–0.71)
.5; 63.4–69.6) 0.88 (0.69–1.14); 0.314; 0.67 (0.63–0.70)
.5; 30.4–36.6) 1.13 (0.88–1.46); 0.314; 0.69 (0.68–0.71)
.5; 62.4–68.6) 0.73 (0.57–0.93); 0.010; 0.64 (0.61–0.68)
.5; 31.4–37.6) 1.37 (1.07–1.76); 0.010; 0.71 (0.69–0.73)
tio, RLS¼ restless legs syndrome, VDR¼ vitamin D3 receptor.
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of RLS. Future studies combining the measurement of serum
TABLE 4. Meanþ SD Age at Onset (Years) of RLS Symptoms andMeanþ SD IRLSSGRS Score AccordingWith the VDRGenotypes.
Both Age at Onset and IRLSSGRS Score Were Dependent of the SNP rs731236 (Kruskal–Wallis Test for Independent Samples
P¼0.009 Each)
VDR rs2228570 Age at Onset (Years) VDR rs731236 Age at Onset (Years)
G/G 43.3 16.3 A/A 52.0 13.9
A/G 44.1 17.1 A/G 43.6 16.9
A/A 43.1 17.0 G/G 40.7 16.2
VDR rs2228570 IRLSSGRS score VDR rs731236 IRLSSGRS score
G/G 24.75 6.82 A/A 23.45 5.96
A/G 24.46 6.81 A/G 24.65 6.74
A/A 24.63 6.01 G/G 27.63 5.73
IRLSSGRS¼ International Restless Legs Syndrome Study Group Rating Scale, RLS¼ restless legs syndrome, SD¼ standard deviation,
SNP¼ single nucleotide polymorphisms, VDR¼ vitamin D3 receptor.
TABLE 5. VDR Genotypes According to Family History or RLS
VDR rs2228570
(Positive/Negative Family History)
Comparison
Values P
VDR rs731236
(Positive/Negative Family History)
Comparison
Values P
Nonmutated 50/35 (58.8%) P ¼ 0.552 32/31 (50.8%) P ¼ 0.284
Heterozygous 51/39 (56.6%) P ¼ 0.940 70/41 (63.1 %) P ¼ 0.851
Homozygous 14/15 (48.3%) P ¼ 0.331 13/17 (43.3%) P ¼ 0.120
Medicine  Volume 94, Number 47, November 2015 VDR Gene and Restless Legs SyndromeA recent experimental study in rats showed that chronic
administration of 1,25-dihydroxyvitamin D induces changes in
several neurotransmitters, which included increase in tyrosine-
hydroxylase (the rate-limiting enzyme in the synthesis of
dopamine) and tryptophan hydroxylase 2 expression, increased
concentrations of dopamine and serotonin metabolites, and
increase in monoamine oxidase A (MAO-A) expression in
the brain.26 These changes can cause alterations in the homeo-
stasis of dopaminergic (of high importance in the pathogenesis
of RLS) and serotonergic neurotransmission. Interestingly,
VDR is widely expressed in the human brain, including the
striatum and the nucleus accumbens.27
VDR s2228570 is a 50 variant which is located between the
blocks 2 and 3 of the VDR gene, its functional consequence is
that T>C eliminates translation start site, and the affected
biological processes and phenotypes include calcium absorp-
tion, calcium accretion to skeleton and bone mineral density at
different ages, vitamin D and parathyroid hormone levels,
calcipotriol response in psoriasis, effects on antimycobacterial
therapy, cell viability in thyroid cancer, and growth inhibition in
breast cancer.28 VDR rs731236 is a 30 variant located in the
block 5 in the VDR gene, its functional consequence is T>C
methylation site, and the affected biological processes and
phenotypes include calcipotriol response in psoriasis, remission
period of chronic plaque psoriasis treated with narrow band
ultraviolet light, tuberculosis susceptibility, effects of vitamin D
supplement in new fractures in postmenopausal women and in
bone mineral density in adolescent girls.28
Data from the present case-control association study
None of the comparisons were statistically significant.
RLS¼ restless legs syndrome, VDR¼ vitamin D3 receptor.suggest a weak association of the VDR rs731236, but not of
the rs2228570 polymorphism, with the risk for RLS, together
with an influence of that SNP in the age at onset and the severity
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.of RLS. These findings are potentially interesting taking in
account the possible relationship between vitamin D and RLS
previously suggested by several preliminary reports.5,8
However, the results of the present study should be taken
with caution because it has several limitations. These include
the relatively low sample size, the lack of previous similar
studies in other populations, and a selection bias with a rela-
tively high male-to-female ratio in our RLS patients (likely due
to the clinical setting of the patients’ recruitment). In addition,
because data on the possible role of vitamin D in the patho-
genesis of RLS are relatively recent, we did not measure serum
vitamin D levels in our patients and controls cohorts at the time
of enrollment to participate in genetic studies.
Taken in account the previously mentioned limitations, our
results point to a modest association of the VDR rs731236
polymorphism with the risk for RLS in Spanish Caucasian
individuals and give a little support to the hypothesis of the
relationship of vitamin D deficiency with the etiopathogenesisvitamin D levels with genotyping of VDR polymorphisms
are warranted.
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